Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02464176 · ClinicalTrials.gov registry record · Phase 4
Systemic Steroids for Peripheral Nerve Blocks
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 115
- Enrollment target
NCT02464176: Completed Phase 4 study, sponsored by Wake Forest University Health Sciences.
NCT02464176 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 115 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02464176, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 115 participants
- Enrollment target
Study Summary
This study will investigate the ability of systemic dexamethasone to prolong the sensory block duration for lumbar plexus nerve blockade.
Primary Outcome
The primary outcome will be duration of sensory blockade in the distribution of the lumbar plexus as determined by pin-prick sensation as tested every two hours with pin-prick sensation.
Interventions
- DRUG Bupivacaine
- DRUG Dexamethasone
- DRUG Epinephrine
- DRUG Saline
- PROCEDURE Lumbar Plexus Nerve Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-01 |
| Phase | Phase 4 |
What the finished NCT02464176 record still lists
NCT02464176 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 5 interventions - of which Bupivacaine is the first listed.
NCT02464176 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02464176 about?
NCT02464176 is a clinical study titled "Systemic Steroids for Peripheral Nerve Blocks". This study will investigate the ability of systemic dexamethasone to prolong the sensory block duration for lumbar plexus nerve blockade.
What is the current status of trial NCT02464176?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 115 participants. The study started on 2015-06. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02464176?
The interventions under investigation include: Bupivacaine (DRUG), Dexamethasone (DRUG), Epinephrine (DRUG), Saline (DRUG), Lumbar Plexus Nerve Block (PROCEDURE).
Who is sponsoring clinical trial NCT02464176?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02464176's enrollment target sits among peer trials
115 718th of 2000 higher than 1,281 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia